Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor

Tengrui Zhang(Peking University), Lixiang Xue(Peking University)
EBioMedicine
February 11, 2022
10.1016/j.ebiom.2022.103872
Cited by 42

Related Papers

EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma
|Molecular Cancer Research|2014|69
Enhancing chemotherapy sensitivity by targeting PcG via the ATM/p53 pathway.
|PubMed|2017|18
Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment
|EBioMedicine|2025|1
Supplementary Methods, Figures 1 - 3, Tables 1 - 3 from EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma
|Unknown|2023|0
Supplementary Methods, Figures 1 - 3, Tables 1 - 3 from EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma
|Unknown|2023|0